Linked Life Data

19691347

Source:http://linkedlifedata.com/resource/pubmed/id/19691347

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2009-9-3
pubmed:abstractText
This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities of the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1520-4804
pubmed:author
pubmed:issnType
Electronic
pubmed:day
10
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5295-8
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
pubmed:affiliation
School of Pharmacy, East China University of Science and Technology, Shanghai, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't